For the new CRBN-recruiting degrader series, the two molecules FMF-06-038 and FMF-06-049 showed significant and improved impact on tau clearance at the 10–100 nM dose range and across two tauopathy neuronal models, including with a shorter treatment of 4 h. Here, MAPT is linked to tauopathy.